US and EU reviews for Astellas' mirabegron move ahead
This article was originally published in Scrip
Executive Summary
Both the US FDA and European Medicines Agency have accepted for review Astellas' first-in-class overactive bladder therapy mirabegron, with the US agency setting a Prescription Drug User Fee Act action date of 29 June 2012.